Execution/quality relapse or a fresh safety event that halts the production ramp and reignites the cash burn
One-line thesis. Boeing is a genuine recovery story — a record $695B backlog, deliveries and revenue climbing, and losses narrowing toward breakeven — but it is still burning cash (FY25 FCF −$1.9B), carrying $43.5B net debt at 5.2× EBITDA, and trading at ~55× FY27 estimated EPS, so the market is already paying for a turnaround management has not yet completed. Fair value sits roughly at today's price; we Watch for proof the ramp holds before paying up.
◆ Synthos call — HoldBA is a solid business largely reflected at ~$235 — fine to keep, no reason to chase; it gets interesting again below ~$200.
Downside Risk (lower = safer)
8/10 · Very High
Negative FCF, 5.2× net-debt/EBITDA, thin equity, no trailing earnings & beta 1.2 — a highly-levered turnaround.
Growth Quality
6/10 · High
Backlog $695B and a real recovery ramp, but still loss-making with no returns on capital yet.
Exponential Potential
3/10 · Low
A recovery, not an exponential — mid-single-digit revenue CAGR, decelerating, $178B cap in a duopoly TAM.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Boeing makes the big passenger jets (the 737, 787, 777) and a lot of military and space hardware. A few years ago it went through crashes, groundings, a factory-quality crisis and COVID, and it has been losing money for years. It's now climbing out of the hole: it's building and delivering more planes, and it has a record pile of orders — about $695 billion — that will take years to work through.
The catch: it's not fixed yet. Boeing still spends more cash than it takes in, it owes a lot of money, and there are no real profits yet to compare the price to. On the numbers that do exist, the stock already assumes the recovery goes well. So you're paying today for a comeback that still has to happen.
Our verdict is Watch — interesting, but wait for proof rather than buy on hope.
Here's what our three scores mean in everyday terms:
Downside Risk 8/10 (high). Lots of debt, still burning cash, no profit cushion, and the stock moves more than the market. If anything goes wrong, it hurts.
Growth Quality 6/10 (decent, improving). The order book is huge and real, and the business is genuinely getting better — but it isn't yet earning good returns.
Exponential Potential 3/10 (low). This is a recovery back to normal, not a rocket ship. There are only two big plane-makers in the world, and the market for jets grows slowly.
The one big worry: another quality slip, safety event, or production halt would stop the recovery cold and turn the cash burn back on — exactly the risk that has bitten Boeing repeatedly.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = BA · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$226.49
Market cap$179B
P/E trailing10×
P/E FY26E / FY27E-1,548× / 55×
EV / Sales2.3×
EV / EBITDA29.5×
Gross margin4.8%
Net margin2.5%
Dividend yield0.00%
Beta1.205
52-wk range$179 – $252
RSI(14)55
50 / 200-DMA$224 / $218
12-mo return+8% (SPY +21%)
Street target$282 ($250–$298)
Analyst grades36 Buy · 13 Hold · 5 Sell
FMP ratingC
Next earnings2026-08-05
What the experts actually said 0 traceable claims on BA · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Boeing (NYSE: BA) is one of two global large-commercial-aircraft makers (the duopoly with Airbus) and a top-tier US defense and space contractor. Founded 1916, headquartered in Arlington, Virginia; ~172,000 employees; CEO Kelly Ortberg. Fiscal year ends December 31. The company runs in three operating segments plus a small finance arm:
Commercial Airplanes (BCA): 737, 787, 777/777X, 767 — passenger and freighter jets plus fleet support. The heart of the recovery and the historic source of the crisis.
Defense, Space & Security (BDS): military aircraft, weapons, satellites, and space (the Boeing-built Space Launch System core stage that propelled Artemis II).
Global Services (BGS): parts, maintenance, training, logistics — the steady, high-margin annuity (18% operating margin).
Boeing Capital: financing (immaterial today).
Revenue mix (from filings):
By segment (FY2025): FMP's file only breaks out Commercial Airplanes at $41.5B for FY2025; the prior full three-way split (FY2024) was BDS $23.9B · BCA $22.9B · Global Services $20.0B. Boeing's own Q1'26 release shows the current mix clearly: BCA $9.2B · BDS $7.6B · BGS $5.4B for the quarter — i.e. commercial is now the largest and fastest-growing segment again, with services the most profitable.
By geography (FY2025): United States $48.1B (~54%) · non-US $41.4B (~46%), led by Asia-ex-China $16.5B, Europe $11.4B and the Middle East $7.0B. Note China — historically a huge Boeing market ($13.8B in 2018) — no longer breaks out as a separate line, a live geopolitical/trade risk (§11).
Backlog is the single most important asset here: a record $695B (over 6,100 commercial airplanes / $576B at BCA, $86B at BDS, $33B at BGS) — years of demand already booked.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of Boeing in the Synthos knowledge base.total_claims = 0; there are zero net-bullish voices and zero cautionary voices distilled for this name. That means the usual highest-value input to a Synthos deep dive — a signed, skill-weighted panel of independent expert claims, each reconciled to a real claim_id — does not exist here, and we will not manufacture one.
Accordingly, everything below is fundamentals-, estimates- and quant-driven: FMP financials and analyst consensus, Boeing's own SEC filings, and the Street's published ratings (which we treat as context, not conviction). Where the Street is cited (36 Buy / 13 Hold / 5 Sell, consensus target $281.56), that is sell-side positioning, not a Synthos conviction signal. Readers should weight this note accordingly: it is a quantitative and structural read, not a high-conviction expert call.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
8 · High
Net-debt/EBITDA 5.2×, FY25 FCF −$1.9B, no trailing earnings, thin/near-negative book equity ($5.5B on $168B assets), beta 1.20. Financially fragile even mid-recovery.
Growth Quality
6 · Moderate
Record $695B backlog and a real delivery ramp give visibility, but the company is still loss-making with negative returns on capital (ROIC −7.7% TTM) — quality is improving, not yet good.
Exponential Potential
3 · Low
~10% revenue CAGR FY25→FY30E and decelerating; a mature duopoly TAM and a $178B cap. This is a recovery to normalized earnings, not a multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–24-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
737 at 42+/mo holds and rises, 777X/737-7/-10 certify and deliver on schedule (2026–27), FCF turns firmly positive, defense stabilizes. FY28E EPS beats to ~$9 and the market pays ~37× on a clean recovery.
~$330 (+46%)
Base(our anchor)
Estimates roughly hit — FY27E EPS ~$4.12, FY28E ~$7.84; a de-levering but still-cyclical industrial earns a ~30× FY28E multiple, discounted back.
~$235 (+4%)
Bear
A fresh quality/safety event or macro air-travel downturn stalls the ramp; FCF stays negative into 2027, forcing more dilution/debt. Multiple de-rates on a ~$4 normalized EPS.
~$130 (−43%)
Synthos fair value = the base case, ~$235 (+4%), with the full $130–$330 span as the honest range. This anchor sits below the Street's $281.56 consensus — we are more cautious because the Street's target discounts a cleaner recovery than the cash flows have yet delivered, and the FY26 estimate is still a loss. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). Boeing is neither today — it is a cyclical recovery:
Forward growth: revenue CAGR FY25→FY30E ~10% ($89.5B → $144.7B on consensus); EPS swings from a small FY26 loss to ~$12.78 by FY30E — but that is recovery off a depressed base, not secular acceleration.
Acceleration (2nd derivative) is negative: the revenue step-up is front-loaded (FY25 already +34.5% on a distorted base as deliveries normalized) and estimates then decelerate — +9% (FY26E) → +15% (FY27E) → +10% (FY28E) → +8% (FY29E) → +9% (FY30E). Per our flagship philosophy we hunt forward next-exponentials, not trailing recoveries; Boeing is the latter.
Room to run: the commercial-aircraft TAM is large but mature and slow-growing, split with Airbus in a stable duopoly. At $178B cap the upside is a re-rate to normalized earnings, not a category-expansion multibagger.
Reinvestment runway: capex is rising (Charleston, St. Louis) but this is catch-up spend to fix and scale existing programs, not high-ROIC greenfield expansion — FCF is still negative.
Exponential Potential: Low. Own the story, if at all, for a cyclical re-rating back to profitability, not for exponential compounding. This is why Boeing sits on the Watch list, not any growth sleeve.
Revenue: FY25 $89.46B, up sharply from FY24 $66.52B as deliveries normalized (FY23 $77.79B). Caveat: FY25 GAAP results are noisy — Q4'25 carried a ~$9.1B non-operating gain that flattered reported EBITDA and quarterly EPS; the underlying business is roughly breakeven.
Margins: gross ~4.8% TTM — razor-thin and cyclical; operating margin barely positive at the core (Q1'26 core operating margin 1.3%). Global Services is the bright spot at 18% operating margin.
Earnings: still effectively loss-making. FY25 GAAP net income $2.24B is almost entirely the Q4 one-off; Q1'26 was a −$0.11 GAAP loss per share. TTM P/E screens ~94× but is not meaningful near breakeven.
Cash flow — the key tell: FY25 operating CF +$1.07B but capex −$2.94B → FCF −$1.88B (still burning). Q1'26 FCF −$1.45B (seasonally weak, but improved from −$2.29B a year ago). This is the number that decides the thesis: watch for FCF to turn durably positive.
Balance sheet — the fragility: net debt $43.5B, net-debt/EBITDA 5.2×, total debt $54.4B against just $5.5B book equity (thin after years of losses, though positive again vs negative in FY24). $20.9B cash + marketable securities and a fully-undrawn $10B revolver provide near-term liquidity — but there is little margin for error.
6. Valuation — priced in or room?
Boeing can't be valued on trailing earnings (there essentially aren't any). On EV/sales 2.3× it looks unremarkable; on forward earnings it looks expensive relative to where the recovery actually is: FY26E is still a loss, FY27E EPS ~$4.12 puts it at ~55× FY27E, falling to ~29× FY28E and ~18× FY30E only if the multi-year ramp fully delivers. In other words, you are paying a growth multiple for a cyclical recovery that hasn't yet reached positive free cash flow. The bull defense is normalization — a company earning $8–12 of EPS by the late-2020s on a record backlog deserves a mid-teens-to-20s multiple, implying meaningful upside if execution holds. Street targets (context): consensus $281.56 (high $298, low $250) — notably, even the Street's low is above today's price, reflecting broad recovery optimism. Our base FV of ~$235 is deliberately below consensus: we discount the same recovery more heavily for the cash burn and leverage still on the page. Not cheap, not obviously dear — fairly valued for a turnaround that must still be proven.
7. Technicals (from the tech block)
Trend:mildly up. $226.49 sits just above the 50-DMA ($223.78) and 200-DMA ($218.32), with the 50 above the 200 — a constructive but not powerful posture. MACD −0.56 (marginally negative, i.e. losing a little short-term momentum).
Location:−10.2% off the 52-week high ($252.15) and +26.4% off the 52-week low ($179.12); max drawdown from peak −15.9%. Mid-range, not extended.
Momentum: RSI(14) 55 — neutral; neither overbought nor oversold, so no timing edge either way.
Relative strength (the tell): BA +8.0% 12-mo vs SPY +20.6% and QQQ +30.3% — a persistent laggard vs both the market and the Nasdaq. 3-mo +9.2% (SPY +13.7%) also trails. The recovery is real but the tape has not rewarded it with leadership.
Read: technicals are neutral-to-slightly-constructive — above rising averages but lagging the market with fading momentum. No urgency to buy; consistent with a Watch.
8. Moat & competitive position
Boeing's moat is structural and durable: it is half of a global duopoly. Building certified large commercial aircraft requires decades of engineering, a global supply chain, an installed base measured in tens of thousands, and near-insurmountable regulatory and switching barriers — airlines are locked into fleets, pilot training and maintenance ecosystems for decades. The $695B backlog is the moat made visible: years of booked demand that Airbus cannot instantly absorb. Defense and Global Services add sticky, long-cycle government and aftermarket revenue.
The flip side: the moat has been self-inflicted-wound-prone. The 737 MAX groundings, the 2024 door-plug quality crisis, certification delays (777X, 737-7/-10) and cost overruns show the barrier protects the franchise but has not protected shareholders from execution failures. The bet is on management (Ortberg) restoring engineering and quality discipline.
Peer set (FMP-supplied, market cap): RTX $268B, Union Pacific $168B (rail — not a true comp), Eaton $155B, Lockheed Martin $126B, General Dynamics $101B, Northrop Grumman $78B, Honeywell $73B, L3Harris $56B, plus small space names Firefly $4.7B and Voyager $2.0B. The cleanest defense/aerospace comps (RTX, LMT, GD, NOC, LHX) are profitable, cash-generative and dividend-paying — the quality bar Boeing must climb back to. Boeing's true commercial competitor, Airbus, is not in the FMP peer list but is the single most important comparison.
9. Management, capital allocation & guidance
Capital allocation: in repair mode. No dividend (suspended since 2020) and no buybacks; capex is rising into the production ramp (Charleston, St. Louis). Priority is stabilizing production, de-levering (Q1'26 consolidated debt fell to $47.2B from $54.1B), and reaching sustained positive FCF. Appropriate for the situation, but it means no capital return to shareholders for now.
Insider activity: the sampled window shows routine director equity awards (phantom stock units, April 2026) and one notable open-market purchase — director Bradley Tilden bought 1,370 shares at $218.50 on 2026-05-20. A director buying in the open market is a mild positive signal; no cluster of alarming discretionary selling appears in the window.
Management's own guidance (half-weighted by design — self-interested): Boeing's Q1'26 earnings release (SEC 8-K, Item 2.02, filed 2026-04-22) is a real earnings release and reads as management's own book. CEO Kelly Ortberg framed it as "a strong start to the year and growing record-breaking backlog," with a "continued focus on safety and quality" while "increasing production." Concrete guidance points management themselves flagged: 737 producing at 42/month, 787 stabilizing at 8/month, expected certification of the 737-7 and 737-10 in 2026 with first delivery in 2027, and 777-9 first delivery anticipated in 2027. These are managements self-interested words and are half-weighted; the delivery/certification dates in particular have slipped repeatedly in Boeing's history and should be treated as targets, not commitments.
10. Catalysts & what to watch
Next earnings: 2026-07-28 (Q2'26; Street EPS −$0.25, revenue ~$23.9B). The key lines: free cash flow (is the burn ending?) and 737/787 delivery rates.
Production rate increases: 737 above 42/month and 787 above 8/month — the FAA-gated throttle on the whole recovery.
Certifications: 737-7, 737-10 (2026) and 777X / 777-9 (first delivery 2027) — each a discrete de-risking or disappointment event.
Free-cash-flow inflection: the single most important tell that the turnaround is real; sustained positive FCF re-rates the stock.
China / trade: resumption (or loss) of the historically large China commercial market.
Thesis tripwires (what would change the call): a fresh safety or quality event that halts a program; two more quarters of negative FCF with no line of sight to positive; a certification slip that pushes 777X/737-7/-10 revenue further right; or renewed dilution.
11. Key risks
Execution / quality relapse (structural, #1): Boeing's recovery has been repeatedly derailed by self-inflicted quality and safety failures. Another such event is the dominant risk and could reignite the cash burn.
Leverage & cash burn: $43.5B net debt at 5.2× EBITDA with still-negative FCF — a stalled recovery pressures the balance sheet and risks further dilution.
Valuation / de-rating: ~55× FY27E and a FY26E loss leave no margin for a delivery miss.
Certification & regulatory timing: 777X and 737-7/-10 dates have slipped before and can slip again.
Cyclicality & macro: commercial aircraft demand is tied to airline profitability and air-travel cycles; a downturn hits an already-fragile balance sheet.
Geopolitical / China: trade tensions and the opaque China market are a swing factor on a large historical revenue pool.
No expert coverage: with zero Synthos KB claims, this call lacks the independent-panel cross-check that higher-conviction notes carry — a diligence gap, stated plainly.
12. Verdict, position sizing & monitoring
Watch. Boeing is a legitimate recovery with a genuine, record $695B backlog, a normalizing delivery ramp, and losses narrowing toward breakeven under a credible management reset. But it is still burning free cash flow, carries heavy leverage (5.2× net-debt/EBITDA), earns negative returns on capital, and already trades at ~55× FY27 estimated EPS — the market is paying for a turnaround that is not yet complete. With no expert coverage in the Synthos KB, there is no conviction panel to lean on; the call is purely quantitative and structural.
Sizing:Watch-list. If entered tactically at all, ≤1–2% with a stop discipline — this is a high-risk-score (8/10) turnaround, not a core holding. The cleaner way to own the recovery is to wait for the FCF inflection and pay up then.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with free cash flow as the decisive metric. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $226.49.
Single biggest risk: an execution/quality relapse or fresh safety event that halts the ramp and turns the cash burn back on.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of BA in the Synthos knowledge base, so this note carries no claim_id citations. The verdict is fundamentals-, estimates- and quant-driven and is labeled as such. Fabricated conviction is structurally impossible (no claims to cite, and none invented).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release filed 2026-04-22. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: Boeing's own guidance (§9) is management's self-interested words, half-weighted by design; historical certification/delivery dates have slipped repeatedly.
Data note: FY2025 GAAP results include a large Q4 non-operating gain that flatters reported EBITDA/EPS; the underlying business is near breakeven. Street price targets are sell-side context, not a Synthos anchor.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").